Online citations, reference lists, and bibliographies.
Please confirm you are human
(Sign Up for free to never see this)
← Back to Search

Pegylated Liposomal Doxorubicin (doxil): Reduced Clinical Cardiotoxicity In Patients Reaching Or Exceeding Cumulative Doses Of 500 Mg/m2.

T. Safra, F. Muggia, S. Jeffers, D. D. Tsao-Wei, S. Groshen, O. Lyass, R. Henderson, G. Berry, A. Gabizon
Published 2000 · Medicine

Save to my Library
Download PDF
Analyze on Scholarcy
BACKGROUND The indications for pegylated liposomal doxorubicin (doxil) are expanding. We, therefore, wished to assess the safety of delivering doses exceeding 500 mg/m2 of doxil to patients with solid tumors. PATIENTS AND METHODS Subjects accrued to eight phase I and II protocol studies conducted at two institutions, were assessed for cardiac function at baseline and at specified intervals by MUGA scans. In this retrospective analysis, the findings of 42 patients, from the total of 237 entered, who had reached or exceeded cumulative doses of 500 mg/m2 (range 500-1500 mg/m2) were reviewed. Changes in left ventricular ejection fraction (LVEF), and in clinical cardiac status were analyzed. Six patients, three who had received prior doxorubicin, also underwent endomyocardial biopsies after cumulative doses of 490-1320 mg/m2. RESULTS None of the 42 patients had clinical congestive heart failure (CHF) secondary to cardiomyopathy. Post doxil MUGA scans were available for 41 of the 42 patients. Five had a drop of 10% or more in LVEF; three of these had received prior doxorubicin. Billingham endomyocardial biopsy scores ranged from 0-1 in five patients, while the sixth had a score of 1.5 after both 900 mg/m2 and 1320 mg/m2 doxil. Of a remaining 195 patients, 1 episode of CHF was recorded in a patient who had received 312 mg/m2 doxil over 120 mg/m2 of mitoxantrone and chest radiation. CONCLUSIONS Cumulative doses in excess of 500 mg/m2 of doxil appear to carry a considerably lesser risk of cardiomyopathy as judged by serial LVEF's and clinical follow-up, than is generally associated with free doxorubicin. Heart biopsies have provided reassuring data in a small number of patients, even if pretreated with doxorubicin. However, since three doxorubicin pretreated patients were among the five experiencing drops in LVEF, more data are warranted on such patients.
This paper references
Cardiotoxicity of epirubicin/paclitaxel-containing regimens: role of cardiac risk factors.
A. Gennari (1999)
Paclitaxel by 3-hour infusion in combination with bolus doxorubicin in women with untreated metastatic breast cancer: high antitumor efficacy and cardiac effects in a dose-finding and sequence-finding study.
L. Gianni (1995)
Risk factors for doxorubicin-induced congestive heart failure.
D. V. Von Hoff (1979)
Pharmacokinetics and tissue distribution of doxorubicin encapsulated in stable liposomes with long circulation times.
A. Gabizon (1989)
Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene-glycol coated liposomes.
A. Gabizon (1994)
Influence of vesicle size, lipid composition, and drug-to-lipid ratio on the biological activity of liposomal doxorubicin in mice.
L. Mayer (1989)
Adriamycin cardiotoxicity: Endomyocardial biopsy evidence of enhancement by irradiation
M. Billingham (1977)
Phase II trial of high-dose liposome-encapsulated doxorubicin with granulocyte colony-stimulating factor in metastatic breast cancer. TLC D-99 Study Group.
C. Shapiro (1999)
Liposomes as in vivo carriers of adriamycin: reduced cardiac uptake and preserved antitumor activity in mice.
A. Gabizon (1982)
Comparison of the cardiotoxic effects of liposomal doxorubicin (TLC D-99) versus free doxorubicin in beagle dogs.
P. M. Kanter (1993)
Liposomal doxorubicin: antitumor activity and unique toxicities during two complementary phase I studies.
B. Uziely (1995)
Doxil in breast cancer.
F. Muggia (1998)
Population pharmacokinetics and pharmacodynamics of pegylated‐liposomal doxorubicin in patients with AIDS‐related Kaposi's sarcoma
M. Amantea (1997)
Strategies for reduction of anthracycline cardiac toxicity.
J. Speyer (1998)
Reduction of the cardiotoxicity of doxorubicin in rabbits and dogs by encapsulation in long-circulating, pegylated liposomes.
P. Working (1999)
Reduced cardiotoxicity of doxorubicin delivered on a weekly schedule. Assessment by endomyocardial biopsy.
F. Torti (1983)
Reduction of doxorubicin cardiotoxicity by prolonged continuous intravenous infusion.
S. Legha (1982)
Sterically stabilized liposomes: improvements in pharmacokinetics and antitumor therapeutic efficacy.
D. Papahadjopoulos (1991)
Phase II trial of liposome-encapsulated doxorubicin, cyclophosphamide, and fluorouracil as first-line therapy in patients with metastatic breast cancer.
V. Valero (1999)
Initial Clinical Evaluation of Pegylated-Liposomal Doxorubicin in Solid Tumors
A. Gabizon (1998)
Phase II study of liposomal doxorubicin in refractory ovarian cancer: antitumor activity and toxicity modification by liposomal encapsulation.
F. Muggia (1997)
The use of cardiac biopsy to demonstrate reduced cardiotoxicity in AIDS Kaposi's sarcoma patients treated with pegylated liposomal doxorubicin.
G. Berry (1998)

This paper is referenced by
Analytical measurement of PEGylated molecules.
T. Cheng (2012)
A designed lipopeptide with a leucine zipper as an imbedded on/off switch for lipid bilayers.
S. Wang (2016)
Malignant epithelioid hemangioendothelioma of the liver successfully treated with pegylated liposomal doxorubicin.
T. Grenader (2011)
Clinical and pathological absence of cardiotoxicity after liposomal doxorubicin.
R. Jones (2004)
Two cholesterol derivative-based PEGylated liposomes as drug delivery system, study on pharmacokinetics and drug delivery to retina.
Sheng-Yong Geng (2014)
Accumulation, internalization and therapeutic efficacy of neuropilin-1-targeted liposomes.
Eric E. Paoli (2014)
2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines
J. Zamorano (2017)
Cardiovascular Effects of Cancer Therapy
D. Briston (2015)
Phase I study of pegylated liposomal doxorubicin and gemcitabine in patients with advanced malignancies
P. Fracasso (2002)
Liposomal drug delivery systems: from concept to clinical applications.
T. Allen (2013)
M. Khalkhali (2015)
Liposomes et formes pégylées : revue des médicaments disponibles
D. Plats (2005)
— miejsce niepegylowanej doksorubicyny liposomalnej The role of anthracyclines in the treatment of advanced breast cancer — the place of nonpegylated liposomal doxorubicin
A. Skrzypczyk (2010)
Nanobiotechnology: A New Generation of Biomedicine — Innovative Nanotechnology in Key Areas of Biomedical Engineering and Cancer Therapy
Prasanna Vidyasekar (2012)
Untersuchungen zum Einfluss von HMG-CoA-Reduktase-Hemmern bei der Anthrazyklin-induzierten Kardiomyopathie
D. Steffen (2011)
Dual HER2 Targeting with Trastuzumab and Liposomal-Encapsulated Doxorubicin (MM-302) Demonstrates Synergistic Antitumor Activity in Breast and Gastric Cancer.
C. Espelin (2016)
Tumor homing peptides as molecular probes for cancer therapeutics, diagnostics and theranostics.
A. Gautam (2014)
Pharmacology of aging and cancer: how useful are pharmacokinetic tests?.
S. Lichtman (2013)
2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines:  The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC).
J. Zamorano (2016)
A cross-sectional study of the availability and pharmacist’s knowledge of nano-pharmaceutical drugs in Palestinian hospitals
Mohyeddin Assali (2018)
Blood Interactions, Pharmacokinetics, and Depth-Dependent Ablation of Rat Mammary Tumors with Photoactivatable, Liposomal Doxorubicin
Kevin A. Carter (2018)
Chapter 8 – Nanoparticle System for Anticancer Drug Delivery: Targeting to Overcome Multidrug Resistance
M. Safhi (2017)
Pegylated liposomal doxorubicin in combination with gemcitabine: a phase II study in anthracycline-naïve and anthracycline pretreated metastatic breast cancer patients
A. Fabi (2005)
Phase I study of weekly paclitaxel and liposomal doxorubicin in patients with advanced solid tumours.
N. Androulakis (2002)
Anthracycline-Associated Cardiotoxicity in Survivors of Childhood Cancer
B. Trachtenberg (2010)
Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer.
A. Buzdar (2005)
Anti-cancer activity of doxorubicin-loaded liposomes co-modified with transferrin and folic acid.
Shravan Kumar Sriraman (2016)
Biodistribution Analysis of NIR-Labeled Nanogels Using in Vivo FMT Imaging in Triple Negative Human Mammary Carcinoma Models.
Mallory R Gordon (2018)
Evaluation of nanomedicines: stick to the basics
S. Mcneil (2016)
An expert opinion on pharmacologic approaches to reducing the cardiotoxicity of childhood acute lymphoblastic leukemia therapies
Patricia E. Zerra (2013)
Second consensus on medical treatment of metastatic breast cancer.
S. Bešlija (2007)
Paediatric Update Preventing organ-specific chemotherapy toxicity
J. Ginsberg (2005)
See more
Semantic Scholar Logo Some data provided by SemanticScholar